• Antiobiotic (Aminoglycosides)
• Bactericidal: inhibits protein synthesis by binding directly to the 30S ribosomal sub unit
• Serious infection cause by sensitive restrains of Pseudomonas aeruginusa, E.coli, Proteus, Klebsiella, staphylococcus
• Uncomplicated UTI caused by organism susceptible to less toxic drugs
• Active tuberculosis, with other antituberculotics
• Mycobacterium avium complex (MAC) infection
• Contraindicated in patients hypersensitive to drug or other aminogycosides
• Use cautiously in patients with impaired renal function or neuromuscular disorders, in neonates and infants and in elderly patients
• Renal impairment
• Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs
• Safety has not been established for treatment period >14 days. A/E
• CNS: neuromuscular blockade
• EENT: ototoxicity (tinnitus, vertigo)
• Renal: nephrotoxicity
• Obtain specimen for culture and sensitivity test before giving first dose. Therapy may begin while awaiting the results.
• Evaluate patient’s hearing before and during therapy if he will be receiving drug for longer than 2 weeks. Notify prescriber if patient has tinnitus, vertigo, or hearing loss.
• Weigh patient and review renal function studies before therapy begins.
• Correct dehydration before therapy because of increase risk of toxicity.
• Obtain blood for peak level 1 hour I.M injection and 30 mins. to 1 hour after IV infusion ends; for trough levels draw blood just before the next dose. Don’t collect blood in a heparinized tube; heparin is incompatible with aminoglycosides.
• Peak drug levels more than 35 mcg/ml and trough levels more than 10...